Nazar Hasan Anber Zainab, Oead Mohammed Saleh Basil, Waheab Al-Obidy Mohammed
Clinical Biochemistry, Department of Pharmacy, Baghdad College of Medical Sciences, Baghdad, Iraq.
Clinical biochemistry, Department of Biochemistry, College of Medicine, University of Baghdad, Iraq, Baghdad, Iraq.
Rep Biochem Mol Biol. 2022 Oct;11(3):524-531. doi: 10.52547/rbmb.11.3.524.
Infection with COVID-19 can cause hepatic damages. Here, we aimed to examine the effect of COVID-19 infection on the serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, and procalcitonin (PCT) concentrations as markers to evaluate the liver function.
In this study, 56 patients infected with COVID- 19 and 28 healthy controls was recruited in Private Nursing Home Hospital of the Medical City, Baghdad. Patients were subdivided according to disease severity into severe and non-severe groups.
The results showed that the mean±SD value of serum AST activity and serum PCT concentrations were elevated significantly in severe group in comparison to healthy control, (p< 0.01, p< 0.001) respectively. Also, the mean ±SD value of serum ALT activity was higher in severe group compared to the healthy subjects and non-severe ones, significantly (p< 0.0001, p< 0.003) respectively. While the mean value of serum albumin concentration of severe patients and non-severe group were significantly decreased compared to healthy subjects. The receiver operating characteristic curve (ROC) revealed that ROC value of albumin (0.992) differentiates between non-severe infected patients and healthy subjects, while the ROC value of serum ALT activity (0.735) differentiates between severe COVID-19 patients and non- severe ones.
Changes of liver function parameters in COVID-19 patients were mild to moderate and measurement of serum ALT activity is the best biomarker in differentiation between non-severe patients and severe ones and albumin concentration is excellent in discrimination between patients and controls.
新型冠状病毒肺炎(COVID-19)感染可导致肝损伤。在此,我们旨在研究COVID-19感染对血清天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、白蛋白和降钙素原(PCT)浓度的影响,以此作为评估肝功能的指标。
本研究在巴格达医疗城私立疗养院医院招募了56例COVID-19感染患者和28名健康对照者。患者根据疾病严重程度分为重症组和非重症组。
结果显示,与健康对照组相比,重症组血清AST活性和血清PCT浓度的平均值±标准差显著升高,分别为(p<0.01,p<0.001)。此外,重症组血清ALT活性的平均值±标准差高于健康受试者和非重症组,差异有统计学意义,分别为(p<0.0001,p<0.003)。而重症患者和非重症组血清白蛋白浓度的平均值与健康受试者相比均显著降低。受试者工作特征曲线(ROC)显示,白蛋白的ROC值(0.992)可区分非重症感染患者和健康受试者,而血清ALT活性的ROC值(0.735)可区分重症COVID-19患者和非重症患者。
COVID-19患者肝功能参数变化为轻至中度,血清ALT活性检测是区分非重症患者和重症患者的最佳生物标志物,白蛋白浓度在区分患者和对照组方面表现优异。